Tim Piotrkowski

Thanks for having me.

At the moment, we don't have any solid prevalence data.

All we've got is proxy measures that we can rely on.

So for example, we know that as of May, 2026, there is, I think a couple hundred thousand posts on Instagram regarding peptides.

And I think a couple hundred thousand videos on TikTok regarding peptides, which is a lot more than what there was last year.

Other sort of proxy measures that we have for us in Australia specifically is a

Needle and syringe providers are seeing a huge influx in service provision for the equipment necessary to inject these substances.

So much so that down the Gold Coast, there is needles and syringe providers that have seen a 600% increase in terms of the service provision from this year versus last year.

Correct.

Yeah.

Even topical application has not the best bioavailability.

So you really do want to inject.

So when we talk about the TGA, I guess they're our medicines or approved product regulation body.

And so when it comes to peptides, like you would have heard and you mentioned earlier, semaglutide, Zempic, Munjaro, Tazepatide, that's their bag.

The peptides that we're talking about here are really either A, underground, we'll call them knockoffs of these substances.

So they're made in and compounded in an unregulated manner and sold on, we'll call it, you know, online or through underground channels online.

And then we've also got all of the other wonderful injectable peptides that aren't necessarily on TGA's radar or anywhere near approval.

So, for example, BPC-157, which is an interesting one.

Yes, it's used for recovery, so for increases collagen synthesis.

That one was on their radar for a while, and I mean, I used...